Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
33
VRDN Quote, Financials, Valuation and Earnings
Last price:
$28.11
Seasonality move
:
-15.82%
Day range:
$27.80 - $29.41
52-week range:
$9.90 - $34.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
32.00x
P/B ratio:
8.48x
Volume:
970.7K
Avg. volume:
1.5M
1-year change:
63.92%
Market cap:
$2.7B
Revenue:
$302K
EPS (TTM):
-$3.53
Analysts' Opinion
-
Consensus RatingViridian Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $42.06, Viridian Therapeutics, Inc. has an estimated upside of 50.75% from its current price of $27.90.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $29.00 representing -- downside risk from its current price of $27.90.
Fair Value
-
According to the consensus of 15 analysts, Viridian Therapeutics, Inc. has 50.75% upside to fair value with a price target of $42.06 per share.
VRDN vs. S&P 500
-
Over the past 5 trading days, Viridian Therapeutics, Inc. has overperformed the S&P 500 by 1.41% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Viridian Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Viridian Therapeutics, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Viridian Therapeutics, Inc. reported revenues of $70.6M.
Earnings Growth
-
Viridian Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Viridian Therapeutics, Inc. reported earnings per share of -$0.42.
Enterprise value:
2.4B
EV / Invested capital:
--
Price / LTM sales:
32.00x
EV / EBIT:
--
EV / Revenue:
33.69x
PEG ratio (5yr expected):
-15.90x
EV / Free cash flow:
-7.31x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$69.7M
Return On Assets:
-43.02%
Net Income Margin (TTM):
-405.28%
Return On Equity:
-47.79%
Return On Invested Capital:
-46.01%
Operating Margin:
-56.7%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $347K | $302K | $70.8M | $86K | $70.6M | |
| Gross Profit | -$730K | -$1.3M | $69.7M | -$244K | $70.3M | |
| Operating Income | -$232M | -$283M | -$328.1M | -$83.5M | -$40M | |
| EBITDA | -$230.9M | -$281.5M | -$327.1M | -$83.2M | -$39.7M | |
| Diluted EPS | -$5.11 | -$4.31 | -$3.53 | -$1.15 | -$0.42 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $217.9M | $431.3M | $323.8M | $767.4M | $571.9M | |
| Total Assets | $221.2M | $440.6M | $328.8M | $771.9M | $577.1M | |
| Current Liabilities | $14.3M | -- | $23.2M | $41.4M | $50.7M | |
| Total Liabilities | $16.6M | -- | $45.2M | $64.4M | $74.2M | |
| Total Equity | $204.6M | $409M | $283.6M | $707.5M | $503M | |
| Total Debt | $2.3M | -- | $21.2M | $22.7M | $23.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$197M | -$326M | -$67.7M | -$84.6M | |
| Cash From Investing | -- | -$335.4M | $238.9M | -$84.7M | $126.1M | |
| Cash From Financing | -- | $621.2M | $56.4M | $245M | $10.9M | |
| Free Cash Flow | -- | -$197.4M | -$326.3M | -$68M | -$84.7M | |
VRDN
Sector
Market Cap
$2.7B
$24M
Price % of 52-Week High
--
48.29%
Dividend Yield
0%
0%
Shareholder Yield
-3.19%
-1.6%
1-Year Price Total Return
63.93%
-22.92%
Beta (5-Year)
0.962
0.500
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$29.40
200-day SMA
Buy
Level
$22.21
Bollinger Bands (100)
Sell
Level
23.66 - 32.8
Chaikin Money Flow
Sell
Level
-3.8M
20-day SMA
Sell
Level
$31.52
Relative Strength Index (RSI14)
Sell
Level
30.29
ADX Line
Sell
Level
34.43
Williams %R
Buy
Level
-98.4375
50-day SMA
Sell
Level
$31.74
MACD (12, 26)
Buy
Level
7.80
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Sell
Level
-1.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.6758)
Sell
CA Score
(Annual)
Level (-0.8008)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.8602)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, VRDN has received 14 Buy ratings 1 Hold ratings, and 0 Sell ratings. The VRDN average analyst price target in the past 3 months is $42.06.
-
Where Will Viridian Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Viridian Therapeutics, Inc. share price will rise to $42.06 per share over the next 12 months.
-
What Do Analysts Say About Viridian Therapeutics, Inc.?
Analysts are divided on their view about Viridian Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Viridian Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $29.00.
-
What Is Viridian Therapeutics, Inc.'s Price Target?
The price target for Viridian Therapeutics, Inc. over the next 1-year time period is forecast to be $42.06 according to 15 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is VRDN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Viridian Therapeutics, Inc. is a Buy. 14 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VRDN?
You can purchase shares of Viridian Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Viridian Therapeutics, Inc. shares.
-
What Is The Viridian Therapeutics, Inc. Share Price Today?
Viridian Therapeutics, Inc. was last trading at $28.11 per share. This represents the most recent stock quote for Viridian Therapeutics, Inc.. Yesterday, Viridian Therapeutics, Inc. closed at $27.90 per share.
-
How To Buy Viridian Therapeutics, Inc. Stock Online?
In order to purchase Viridian Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get VRDN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VRDN
Sector
P/E ratio
--
23.25x
PEG ratio
-15.90x
-0.01x
P/B ratio
8.48x
1.73x
Price / LTM sales
32.00x
1.51x
Growth Metrics
VRDN
Sector
Revenue growth
81958.14%
3.51%
Earnings growth
63.36%
11.14%
Revenue (5-year growth)
-41.64%
6.27%
Earnings forecast
-$1.00
-$0.19
Profitability
VRDN
Sector
Profitability FY 2024
-$938K
$2.7M
Return on invested capital
-46.01%
-33.58%
Return on assets
-43.02%
-29.74%
Return on equity
-47.79%
-38.98%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
4
Balance Sheet
VRDN
Sector
Total cash
$490.9M
$24.9M
Short term investments
$618M
$23.9M
Total assets
$742.4M
$71.6M
Long term debt
$23.1M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 17
Cooper-Standard Holdings, Inc. [CPS] is down 2.63% over the past day.
Buy
58
TPH alert for Feb 17
Tri Pointe Homes, Inc. [TPH] is down 0.17% over the past day.
Sell
20
IRON alert for Feb 17
Disc Medicine, Inc. [IRON] is up 15.21% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
